Erstlinientherapie beim nichtresektablen/metastasierten nichtklarzelligen NierenzellkarzinomRandomisierte Phase-II-Open-label-Studie mit Nivolumab in Kombination mit Ipilimumab versus Sunitinibmonotherapie bei Patienten mit zuvor unbehandeltem fortgeschrittenen (inoperablen oder metastasierenden) nichtklarzelligen Nierenzellkarzinom – SUNNIFORECASTFirst-line therapy for non-resectable metastatic non-clear cell renal cell carcinomaA Phase 2, Randomized, open-label Study of Nivolumab Combined with Ipilimumab versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma – SUNNIFORECAST

被引：0
|
作者：
H. Rexer
T. Steiner
L. Bergmann
机构：
[1] AUO-Geschäftsstelle,Arbeitsgemeinschaft Urologische Onkologie
[2] Deutsche Krebsgesellschaft e. V.,Medizinische Klinik II
[3] Universitätsklinikum Frankfurt,undefined
来源：
Forum | 2019年 / 34卷 / 6期
关键词：
D O I：
10.1007/s12312-019-00715-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：565 / 567
页数：2
相关论文
共 19 条
  • [1] Phase-II-Studie zur Erstlinientherapie beim nichtresektablen/metastasierten nichtklarzelligen NierenzellkarzinomEine randomisierte, offene Phase-II-Studie von Nivolumab in Kombination mit Ipilimumab gegenüber Sunitinib-Monotherapie bei Patienten mit zuvor unbehandeltem und fortgeschrittenem (inoperablem oder metastasiertem) nichtklarzelligem Nierenzellkarzinom – SUNNIFORECAST AN 41/16 der AUOPhase II trial on first-line treatment in non-resectable/metastatic non-clear cell renal cell carcinomaA randomized, open-label phase II trial of nivolumab in combination with ipilimumab vs. sunitinib monotherapy in patients with previously untreated advanced (inoperable or metastatic) non-clear cell renal cell carcinoma—SUNNIFORECAST AN 41/16 of the AUO
    H. Rexer
    L. Bergmann
    T. Steiner
    Forum, 2021, 36 (5) : 411 - 413
  • [2] A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO
    Rexer, H.
    Bergmann, L.
    Steiner, T.
    AKTUELLE UROLOGIE, 2020, 51 (03) : 236 - 238
  • [3] Nivolumab combined with Ipilimumab versus Sunitinib-Monotherapy-SUNNIFORECAST - AN 41/16 of the AUO Phase-II randomized, open-label Study in Patients with previously untreated and advanced (unresectable or metastatic) non-clear cell Renal Cell Carcinoma
    Rexer, H.
    Steiner, T.
    Bergmann, L.
    UROLOGE, 2017, 56 (06): : 802 - 803
  • [4] Nivolumab in Kombination mit Ipilimumab vs. Sunitinib-Monotherapie – SUNNIFORECAST – AN 41/16 der AUO Randomisierte offene Phase-II-Studie bei Patienten mit nicht vorbehandeltem und fortgeschrittenem (nicht-resektabel oder metastatisch) nicht-klarzelligem Nierenzellkarzinom. Nivolumab combined with ipilimumab versus sunitinib monotherapy—SUNNIFORECAST AN 41/16 of the AUOA phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma
    H. Rexer
    T. Steiner
    L. Bergmann
    Der Urologe, 2017, 56 (6): : 802 - 803
  • [5] A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST)
    Ahrens, M.
    Escudier, B.
    Haanen, J.
    Gross-Goupil, M.
    Boleti, E.
    Gravis, G.
    Grimm, M. -O.
    Negrier, S.
    Bedke, J.
    Barthelemy, P.
    Castellano, D.
    Mellado, B.
    Ivanyi, P.
    Rottey, S.
    Florcken, A.
    Maroto, J. P.
    Rodriguez, Suarez C.
    Oosting, S. F.
    Panic, A.
    Zschabitz, S.
    Boegemann, M.
    Kopecky, J.
    Deckbar, D.
    Hartmann, A.
    Bergmann, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 317 - 318
  • [6] SUNNIFORECAST - A phase II study of Nivolumab in combination with Ipilimumab versus Standard of care in advanced or metastatic non-clear cell renal cell carcinoma
    Scheich, S.
    Ahrens, M.
    Goekbuget, N.
    Boleti, E.
    Burkholder, I
    Escudier, B. J.
    Goebell, P. J.
    Gruenwald, V
    Gschwend, J.
    Retz, M.
    Hartmann, A.
    Maroto Rey, J. P.
    Miller, K.
    Grimm, M. -O
    Siemer, S.
    Panic, A.
    Bergmann, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 205 - 205
  • [7] A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated metastatic renal cell carcinoma
    Hammers, H.
    Sternberg, C.
    Mcdermott, D. F.
    Larkin, J.
    Ravaud, A.
    Rini, B.
    Sharma, P.
    Bhagavatheeswaran, P.
    Gagnier, P.
    Motzer, R.
    BJU INTERNATIONAL, 2014, 114 : 9 - 9
  • [8] A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast)
    Ahrens, Marit
    Escudier, Bernard
    Boleti, Ekaterini
    Grimm, Marc-Oliver
    Goupir, Marine Gross
    Barthelemy, Pilippe
    Gravis, Gwenaelle
    Bedekes, Jens
    Ivanyi, Philipp
    Panic, Andrej
    Zschaebitz, Stefanie
    Neyrieru, Sylvie
    Mellado, Begona
    Biel, Anika
    Wadell, Tom
    Pablo Maroto, Jose
    Retz, Margitta
    Boegemann, Martin
    Rottey, Sylvie
    Haanen, John
    Oosting, Sjoukje
    Castellano, Daniel
    Hartmann, Arndt
    Bergmann, Lothar
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 226 - 226
  • [9] A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
    Ahrens, Marit
    Escudier, Bernard
    Boleti, Ekaterini
    Grimm, Marc-Oliver
    Gross-Goupil, Marine
    Barthelemy, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
    Ahrens, Marit
    Escudier, Bernard
    Haanen, John B. A. G.
    Boleti, Ekaterini
    Goupil, Marine Gross
    Grimm, Marc-Oliver
    Negrier, Sylvie
    Barthelemy, Philippe
    Gravis, Gwenaelle
    Ivanyi, Philipp
    Bedke, Jens
    Castellano, Daniel
    Panic, Andrej
    Mellado, Begona
    Maroto-Rey, Pablo
    Rottey, Sylvie
    Zschaebitz, Stefanie
    Deckbar, Dorothee
    Hartmann, Arndt
    Bergmann, Lothar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12